title: High incidence of discontinuations due to adverse events in patients treated with ceftaroline.
abstract: OBJECTIVE
  To determine clinical outcomes in patients who received ceftaroline (Teflaro) 600 mg intravenously every 8 or 12 hours after failing or developing intolerance to first-line agents including vancomycin, daptomycin, or linezolid.
  
  
  METHODS
  Retrospective chart review and review of the literature.
  
  
  METHODS
  Large academic medical center and regional Level 1 trauma and burn center.
  
  
  METHODS
  Twelve patients who received ceftaroline for the treatment of refractory methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus infections between March 2011 and October 2012.
  
  
  RESULTS
  Ceftaroline was discontinued in 9 (75%) of 12 patients secondary to adverse effects. The average age of patients who discontinued ceftaroline was 53 years, with a mean body mass index of 29 kg/m(2) and an average of four comorbidities (range one to eight). The median time to discontinuation due to perceived adverse effect was 22 days (range 5-62 days). The reasons for discontinuation of therapy were hematologic toxicities in seven patients and severe rash in two patients. Two patients completed therapy without documented adverse events, and one patient died on day 9 of ceftaroline therapy.
  
  
  CONCLUSIONS
  When given for off-label indications to 12 patients at our institutions, ceftaroline was associated with an unexpectedly high rate (75%) of discontinuation due to perceived adverse events, including hematologic toxicities and rash.
authors.affiliation: Department of Pharmacy, University of Washington Medical Center, Seattle, Washington; School of Pharmacy, University of Washington, Seattle, Washington.
authors.forename: Rupali
authors.initials: R
authors.lastname: Jain
authors.forename: Jeannie D
authors.initials: JD
authors.lastname: Chan
authors.forename: Lisa
authors.initials: L
authors.lastname: Rogers
authors.forename: Timothy H
authors.initials: TH
authors.lastname: Dellit
authors.forename: John B
authors.initials: JB
authors.lastname: Lynch
authors.forename: Paul S
authors.initials: PS
authors.lastname: Pottinger
mesh_terms: D061605:Administration, Intravenous; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002511:Cephalosporins / Q000008:administration & dosage* / Q000009:adverse effects*; D006402:Hematologic Diseases / Q000139:chemically induced* / Q000175:diagnosis* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D000097583:Ceftaroline
chemical_list: D002511:Cephalosporins; D000097583:Ceftaroline
keywords: adverse events; ceftaroline; hematologic toxicities; methicillin-resistant Staphylococcus aureus; rash